OBJECTIVE: Posttraumatic epilepsy (PTE) is a significant complication following traumatic brain injury (TBI), yet the role of genetic variation in modulating PTE onset is unclear. We hypothesized that TBI-induced inflammation likely contributes to seizure development. We assessed whether genetic variation in the interleukin-1beta (IL-1β) gene, IL-1β levels in cerebrospinal fluid (CSF) and serum, and CSF/serum IL-1β ratios would predict PTE development post-TBI. METHODS: We investigated PTE development in 256 Caucasian adults with moderate-to-severe TBI. IL-1β tagging and functional single nucleotide polymorphisms (SNPs) were genotyped. Genetic variance and PTE development were assessed. Serum and CSF IL-1β levels were collected from a subset of subjects (n = 59) during the first week postinjury and evaluated for their associations with IL-1β gene variants, and also PTE. Temporally matched CSF/serum IL-1β ratios were also generated to reflect the relative contribution of serum IL-1β to CSF IL-1β. RESULTS: Multivariate analysis showed that higher CSF/serum IL-1β ratios were associated with increased risk for PTE over time (p = 0.008). Multivariate analysis for rs1143634 revealed an association between the CT genotype and increased PTE risk over time (p = 0.005). The CT genotype group also had lower serum IL-1β levels (p = 0.014) and higher IL-1β CSF/serum ratios (p = 0.093). SIGNIFICANCE: This is the first report implicating IL-1β gene variability in PTE risk and linking (1) IL-1β gene variation with serum IL-1β levels observed after TBI and (2) IL-1β ratios with PTE risk. Given these findings, we propose that genetic and IL-1β ratio associations with PTE may be attributable to biologic variability with blood-brain barrier integrity during TBI recovery. These results provide a rationale for further studies (1) validating the impact of genetic variability on IL-1β production after TBI, (2) assessing genetically mediated signaling mechanisms that contribute to IL-1β CSF/serum associations with PTE, and (3) evaluating targeted IL-1β therapies that reduce PTE. Wiley Periodicals, Inc.
OBJECTIVE:Posttraumatic epilepsy (PTE) is a significant complication following traumatic brain injury (TBI), yet the role of genetic variation in modulating PTE onset is unclear. We hypothesized that TBI-induced inflammation likely contributes to seizure development. We assessed whether genetic variation in the interleukin-1beta (IL-1β) gene, IL-1β levels in cerebrospinal fluid (CSF) and serum, and CSF/serum IL-1β ratios would predict PTE development post-TBI. METHODS: We investigated PTE development in 256 Caucasian adults with moderate-to-severe TBI. IL-1β tagging and functional single nucleotide polymorphisms (SNPs) were genotyped. Genetic variance and PTE development were assessed. Serum and CSF IL-1β levels were collected from a subset of subjects (n = 59) during the first week postinjury and evaluated for their associations with IL-1β gene variants, and also PTE. Temporally matched CSF/serum IL-1β ratios were also generated to reflect the relative contribution of serum IL-1β to CSF IL-1β. RESULTS: Multivariate analysis showed that higher CSF/serum IL-1β ratios were associated with increased risk for PTE over time (p = 0.008). Multivariate analysis for rs1143634 revealed an association between the CT genotype and increased PTE risk over time (p = 0.005). The CT genotype group also had lower serum IL-1β levels (p = 0.014) and higher IL-1β CSF/serum ratios (p = 0.093). SIGNIFICANCE: This is the first report implicating IL-1β gene variability in PTE risk and linking (1) IL-1β gene variation with serum IL-1β levels observed after TBI and (2) IL-1β ratios with PTE risk. Given these findings, we propose that genetic and IL-1β ratio associations with PTE may be attributable to biologic variability with blood-brain barrier integrity during TBI recovery. These results provide a rationale for further studies (1) validating the impact of genetic variability on IL-1β production after TBI, (2) assessing genetically mediated signaling mechanisms that contribute to IL-1β CSF/serum associations with PTE, and (3) evaluating targeted IL-1β therapies that reduce PTE. Wiley Periodicals, Inc.
Authors: Robert S Fisher; Walter van Emde Boas; Warren Blume; Christian Elger; Pierre Genton; Phillip Lee; Jerome Engel Journal: Epilepsia Date: 2005-04 Impact factor: 5.864
Authors: Teresa Ravizza; Sian-Marie Lucas; Silvia Balosso; Liliana Bernardino; George Ku; Francesco Noé; Joao Malva; John C R Randle; Stuart Allan; Annamaria Vezzani Journal: Epilepsia Date: 2006-07 Impact factor: 5.864
Authors: D H Smith; X H Chen; J E Pierce; J A Wolf; J Q Trojanowski; D I Graham; T K McIntosh Journal: J Neurotrauma Date: 1997-10 Impact factor: 5.269
Authors: G Schmitz; W E Kaminski; M Porsch-Ozcürümez; J Klucken; E Orsó; M Bodzioch; C Büchler; W Drobnik Journal: Pathobiology Date: 1999 Impact factor: 4.342
Authors: Linda Holtman; Erwin A van Vliet; Eleonora Aronica; Diana Wouters; Wytse J Wadman; Jan A Gorter Journal: Epilepsia Date: 2013-02-08 Impact factor: 5.864
Authors: Matthew L Diamond; Anne C Ritter; Edwin K Jackson; Yvette P Conley; Patrick M Kochanek; Detlev Boison; Amy K Wagner Journal: Epilepsia Date: 2015-06-04 Impact factor: 5.864
Authors: Melissa L Barker-Haliski; Taylor D Heck; E Jill Dahle; Fabiola Vanegas; Timothy H Pruess; Karen S Wilcox; H Steve White Journal: Epilepsia Date: 2016-10-14 Impact factor: 5.864
Authors: Elizabeth Newell; David K Shellington; Dennis W Simon; Michael J Bell; Patrick M Kochanek; Keri Feldman; Hülya Bayir; Rajesh K Aneja; Joseph A Carcillo; Robert S B Clark Journal: Pediatr Crit Care Med Date: 2015-07 Impact factor: 3.624
Authors: Asla Pitkänen; Katarzyna Lukasiuk; F Edward Dudek; Kevin J Staley Journal: Cold Spring Harb Perspect Med Date: 2015-09-18 Impact factor: 6.915